Literature DB >> 10388127

The Importance of Planned Dose of Chemotherapy on Time: Do We Need to Change Our Clinical Practice?

.   

Abstract

INTRODUCTION: Dose-limiting hematological toxicity is encountered with many chemotherapy regimens; it is common clinical practice to reduce the dosage or delay the administration of the next cycle of chemotherapy in response to toxicity [1, 2]. Reducing or delaying the dose, however, will reduce the dose intensity of treatment. This practice may achieve some reduction in toxicity, but may also decrease the therapeutic effect of the treatment. This review will examine the evidence for a relationship between reductions in dose intensity of treatment and suboptimal outcome, as distinct from studies seeking to improve survival by using dose-intensified chemotherapy regimens.

Entities:  

Year:  1998        PMID: 10388127

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  16 in total

1.  Development of angiotensin II (1-7) analog as an oral therapeutic for the treatment of chemotherapy-induced myelosuppression.

Authors:  Kevin Gaffney; Michael Weinberg; Maira Soto; Stan Louie; Kathleen Rodgers
Journal:  Haematologica       Date:  2018-07-05       Impact factor: 9.941

Review 2.  Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?

Authors:  Daniel Crona; Federico Innocenti
Journal:  Biomark Med       Date:  2012-06       Impact factor: 2.851

3.  Is it important to maintain high-dose intensity chemotherapy in the treatment of adults with osteosarcoma?

Authors:  I Kushnir; Y Kolander; J Bickels; Y Gortzak; G Flusser; J Issakov; O Merimsky
Journal:  Med Oncol       Date:  2014-04-10       Impact factor: 3.064

4.  Clinico-pathological Study of Limb Salvage Surgery for Osteosarcoma: Experience in a Rural Cancer Center.

Authors:  Divya Vijayanarasimha; Sangeetha K Nayanar; Syam Vikram; Vijay M Patil; Satheesh Babu
Journal:  Indian J Surg Oncol       Date:  2016-08-30

Review 5.  Management of Mucositis During Chemotherapy: From Pathophysiology to Pragmatic Therapeutics.

Authors:  Ysabella Z A Van Sebille; Romany Stansborough; Hannah R Wardill; Emma Bateman; Rachel J Gibson; Dorothy M Keefe
Journal:  Curr Oncol Rep       Date:  2015-11       Impact factor: 5.075

Review 6.  Targeting pan-essential genes in cancer: Challenges and opportunities.

Authors:  Liang Chang; Paloma Ruiz; Takahiro Ito; William R Sellers
Journal:  Cancer Cell       Date:  2021-01-14       Impact factor: 31.743

7.  Plasma Cytokeratin 18 and fecal Alpha-1 Antitrypsin concentrations in dogs with osteosarcoma receiving carboplatin chemotherapy.

Authors:  Kathryn Taikowski; Adam J Rudinsky; Darian S Louke; Emma Warry; Joelle M Fenger
Journal:  Vet Med Sci       Date:  2020-11-22

8.  Clostridium difficile-associated diarrhea in radiooncology: an underestimated problem for the feasibility of the radiooncological treatment?

Authors:  Matthias G Hautmann; Matthias Hipp; Oliver Kölbl
Journal:  Radiat Oncol       Date:  2011-08-01       Impact factor: 3.481

9.  The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people.

Authors:  T Kalsi; G Babic-Illman; P J Ross; N R Maisey; S Hughes; P Fields; F C Martin; Y Wang; D Harari
Journal:  Br J Cancer       Date:  2015-04-14       Impact factor: 7.640

Review 10.  Bringing a genomic perspective to the safety of drug treatment in oncology.

Authors:  Federico Innocenti
Journal:  F1000Res       Date:  2017-03-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.